Clinical Trial Update: Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and protective efficacy of a single-dose live attenuated tetravalent dengue vaccine TV005. The study used rDEN3Δ30 as the challe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• TV005

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED